参附注射液治疗急性心肌梗死临床观察

目的：探讨参附注射液治疗急性心肌梗死患者的临床效果。方法将86例急性心肌梗死患者按随机数字表法分为两组,每组34例,均予以心血管内科常规治疗,研究组在此基础上联合参附注射液治疗,观察14 d。于治疗前后,抽取患者空腹静脉血检测血清中 C 反应蛋白、N末端脑钠肽前体水平,同时测定患者的心脏指数及左室射血分数。结果治疗前两组各项指标水平比较差异无显著性(P >0.05)。治疗后两组 C 反应蛋白、N 末端脑钠肽前体水平均较治疗前显著降低(P <0.01),研究组显著低于对照组(P <0.01);心脏指数及左室射血分数均较治疗前显著升高(P <0.01),研究组显著高于对照组(P <0.01)。结论参附注射液可显著降低急性心肌梗死患者的炎症反应,改善患者的心功能,提高临床疗效,有利于预后。

Clinical observation of shenfu injection in the treatment of a-cute myocardial infarction

Objective To explore the efficacy of shenfu injection in the treatment of acute myocardial in-farction (AMI).Methods Eighty-six AMI patients were assigned to two groups of 34 ones each,both groups received cardiovascular routine treatment,and research group was plus shenfu injection for 14 days.Before and after treatment fasting serum C-reactive protein (CRP)and N-terminal pro-brain natri-uretic peptide (NTPBNP)levels detected,cardiac index and left ventricular ejection fraction (LVEF)sim-ultaneously determined.Results Before treatment there were no significant group differences in all inde-xes levels (P >0.05).After treatment CRP and NTPBNP levels of both groups lowered more significantly compared with pretreatment (P < 0.01 )and those were significantly lower in research than in control group (P <0.01);cardiac indexes and LVEFs of both group heightened more significantly compared with pretreatment (P <0.01)and those were significantly higher in research than in control group (P <0.01). Conclusion Shenfu injection could notably lower inflammatory reaction in AMI patients,improve heart function,boost clinical efficacy,and is beneficial to prognosis.